Eisai Co., Ltd. is confident that it has the necessary data to convince the US Centers for Medicare and Medicaid Services to grant broader coverage for its Biogen, Inc.-partnered Alzheimer’s drug candidate lecanemab, if the US Food and Drug Administration approves it next month – setting it up for a potentially much better commercial outlook than the firms’ Aduhelm faced. Many in the Alzheimer's field, impressed with the quality and amount of data presented from the Phase III Clarity AD clinical trial, are optimistic about lecanemab’s chances as well.
The Centers for Medicare and Medicaid Services (CMS) issued a national coverage decision (NCD) providing for coverage with evidence development (CED) in response to Biogen/Eisai’s request for Medicare coverage of...